Tag Archives: Drug

It has come to this: ignore vaccines-in-animals drug industry PR & news

A long-haired male golden hamster (via Wikipedia & Creative Commons) Earlier this week, a powerful opinion piece, “It Has Come To This:  Ignore the CDC,”  co-authored by former National Institutes of Health director Harold Varmus,  was published in the New York Times. That’s on the science side. On the PR and journalism side, it has… Read More »

Repurposing a cancer drug to reduce COVID-19 lung inflammation

Winship Cancer Institute of Emory University (Winship) and Emory investigators are testing whether an anticancer drug can reduce lung inflammation in hospitalized COVID-19 patients, possibly preventing the need for intubation and lowering mortality. The drug is called duvelisib, and it was FDA-approved in 2018 for the treatment of relapsed or refractory chronic lymphocytic leukemia or… Read More »

Drug company influence on journalism

Many times through the years, HealthNewsReview.org has criticized the National Press Foundation in Washington, DC, for accepting drug company funding for journalism training.  (See articles from June 2009, July 2009, August 2010, September 2010, October 2010, March 2014, March 2015, December 2015, November 2019. I may have missed a few, but you get the picture.) They’re doing it… Read More »

UnitedHealthcare spurns Gilead’s newer PrEP drug Descovy as Truvada generic looms: report

UnitedHealthcare has a history of limiting HIV drug costs, including offering cash incentives to patients who opt for low-priced regimens. Now, in a potentially major blow to HIV giant Gilead Sciences, the insurer has set its eyes on one of the California drugmaker’s new therapies. Gilead’s new HIV PrEP option, Descovy, will no longer be covered… Read More »

Tremfya (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis

Print this page HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] Tremfya is the first treatment… Read More »